VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference
05. September 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
09. August 2019 08:00 ET
|
VBI Vaccines, Inc.
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference
05. August 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29. Juli 2019 08:00 ET
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
01. Juli 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
20. Juni 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
17. Juni 2019 06:00 ET
|
VBI Vaccines, Inc.
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
16. Juni 2019 12:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Results of Annual General Meeting
13. Juni 2019 17:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
04. Juni 2019 08:00 ET
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...